Individuals With Alcohol-Related Hepatocellular Carcinoma Have Reduced OS

Share this content:
Alcohol-related HCC was more likely to be diffuse and detected in patients with a worse performance status and liver function, research indicates.
Alcohol-related HCC was more likely to be diffuse and detected in patients with a worse performance status and liver function, research indicates.

(HealthDay News) -- Reduced overall survival (OS) is seen for patients with alcohol-related hepatocellular carcinoma (HCC), according to a study published online March 28 in Cancer.

Charlotte E. Costentin, M.D., from the Public Hospital System of Paris, and colleagues compared HCC characteristics and outcomes among an alcohol-related group (group A; 582 patients) and a nonalcohol-related group (group NA; 312 patients).

The researchers found that HCC that was alcohol-related was more likely to be diffuse and detected in patients with a worse performance status and worse liver function. The median OS was 9.7 and 5.7 months in groups NA and A, respectively (P = 0.0002), after adjustments for a lead-time bias; in alcohol-abstinent and alcohol-non-abstinent groups, median OS was 5.8 and 5.0 months, respectively (P = 0.09). When survival was assessed at each Barcelona Clinic Liver Cancer (BCLC) stage, the prognostic role of alcohol disappeared. Increased lead time-adjusted median OS was seen for patients with HCC detected during a cirrhosis follow-up program (199 patients) compared to those with HCC diagnosed incidentally (11.7 versus 5.4 months; P < 0.0001).

"In comparison with patients with non-alcohol-related HCC, patients with alcohol-related HCC have reduced OS, mainly because of worse liver function and tumor characteristics at diagnosis, as attested by similar survival within each BCLC stage," the authors write.

Abstract/Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs